Bonraybio Co., Ltd. (6955) Fair Value & Analysis

Healthcare · TW · Market cap 3.3B TWD (≈ $105M)

What is Bonraybio Co., Ltd. really worth?

BC Bonraybio Co., Ltd. 6955 · TW

Price100.00 TWD

Fair Value60.63 TWD

Upside−39.4%

Quality68/100

A solid business, but trading 65% above our fair value of 60.63 TWD.

As of Aug 28, 2026, the fair value of Bonraybio Co., Ltd. is 60.63 TWD per share against a price of 100.00 TWD, so the fair value sits 39% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Bonraybio Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 3y +42.3 %/yr)

✓Highly profitable · 32.5% net margin

✓generates free cash flow

✓Wide moat 79/100

Risks

!Mixed vs. peers (7/13)

For context

·1.50% dividend yield

Evidence: High Range 47.68 TWD – 93.52 TWD

Fair value as of: Aug 28, 2026

From 26 valuation models · updated 9 days ago

Fair value updated Aug 28, 2026, revised from 74.95 TWD to 60.63 TWD (−19.1%) since Aug 13, 2026. Share price +2.2% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

The price sits above even our optimistic bull case (93.52 TWD). The favourable scenario is already priced in.
Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
A fairly wide model range (47.68 TWD to 93.52 TWD) leaves room in how you read the outcome.

Price vs Fair Value (3 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.

How to read this chart

37‑month range 46.01 TWD – 966,028 TWD · fair‑value band 47.68 TWD – 93.52 TWD · the 100.00 TWD price screens above the 60.63 TWD fair value. Dashed = 300-day average. As of Aug 28, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Bonraybio Co., Ltd. (6955) currently trades at 100.00 TWD, while our model-based Fair Value estimate is 60.63 TWD, implying the stock looks roughly 64.9% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 155.33 TWD per share, and 6 of the 26 models we run sit above the 100.00 TWD price. Bear case: the Asset-Based group reads lowest at 14.02 TWD, and 20 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Bonraybio Co., Ltd. generated revenue of 320M TWD at a net margin of 32.0%. Revenue grew 18.8% year over year. It earns a return on equity of 17.2%. The stock trades on a trailing P/E of 24.3. Fundamentals as of Aug 28, 2026

Our scenario range runs from 47.68 TWD (bear case) to 93.52 TWD (bull case); at 100.00 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −39%, 6955 screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 1.78 TWD per share, which is 2.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence

Highest evidence

FCF DCF best evidence 42.96 TWD 61.36 TWD 118.75 TWD 70

EPV 32.26 TWD 35.96 TWD 39.15 TWD 68

Growth DCF 40.88 TWD 69.82 TWD 116.44 TWD 68

All 26 models by family

DCF Models

FCF DCF best evidence 42.96 TWD 61.36 TWD 118.75 TWD 70

Owner Earnings 48.42 TWD 96.54 TWD 193.86 TWD 64

5Y Revenue Exit 35.19 TWD 53.88 TWD 92.94 TWD 63

5Y EBITDA Exit 47.27 TWD 78.29 TWD 139.18 TWD 65

5Y P/E Exit 59.33 TWD 126.80 TWD 219.63 TWD 60

10Y Revenue Exit 37.02 TWD 69.19 TWD 89.20 TWD 60

10Y EBITDA Exit 46.55 TWD 94.60 TWD 178.96 TWD 58

10Y P/E Exit 55.15 TWD 119.96 TWD 228.46 TWD 54

Earnings-Based

Graham-Dodd 22.73 TWD 158.54 TWD 222.49 TWD 59

Lynch FV 81.91 TWD 117.01 TWD 152.12 TWD 57

PEG = 1.0 81.91 TWD 117.01 TWD 152.12 TWD 53

EPV 32.26 TWD 35.96 TWD 39.15 TWD 68

Dividend Discount

Gordon GGM 9.27 TWD 18.46 TWD 27.96 TWD 62

DDM Multi-Stage 9.27 TWD 15.96 TWD 19.49 TWD 62

Multiples

P/E Multiple 55.16 TWD 73.55 TWD 91.94 TWD 63

P/S Multiple 26.22 TWD 34.97 TWD 43.71 TWD 58

P/B Multiple 42.63 TWD 56.84 TWD 71.04 TWD 55

EV/EBIT 50.41 TWD 64.27 TWD 78.12 TWD 63

EV/EBITDA 47.68 TWD 60.63 TWD 73.57 TWD 64

EV/Revenue 29.83 TWD 38.82 TWD 47.81 TWD 52

Asset-Based

NCAV (Graham) 10.46 TWD 14.02 TWD 20.92 TWD 51

Growth DCF

Growth DCF 40.88 TWD 69.82 TWD 116.44 TWD 68

Rev-Margin DCF 37.90 TWD 60.36 TWD 107.39 TWD 63

Economic Profit

Residual Income 21.37 TWD 28.33 TWD 83.13 TWD 61

ROIC Compounder 40.61 TWD 59.33 TWD 70.13 TWD 66

Growth Earnings

Growth-Adj P/E 108.73 TWD 155.33 TWD 201.93 TWD 63

Widest divergence: Growth Earnings (155.33 TWD) versus Asset-Based (14.02 TWD). Highest evidence: FCF DCF (70).

Notify me when 6955 reaches fair value

Put 6955 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 24.3

P/S ratio 8.12 P/E × margin

EPS (TTM) 4.12 TWD price ÷ EPS = P/E 24.3

Dividend yield 1.5% payout 36.4%

Net margin 33.5% FY2025

Return on equity 17.2% TTM

More key figures

Profitability

Return on assets (EBIT) 2.7% avg 5y

Operating margin 30.2% TTM

Growth

Revenue (TTM) 320M TWD TTM

Revenue growth (YoY) +18.8% 3y avg +42.3%

EPS growth (YoY) −1.0%

Balance sheet & cash flow

Free cash flow 65.8M TWD FY2025

Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 69 · Market factors (momentum, volatility) 36

Profitability 66

Margins and returns on capital today

Quality Growth 78

Are margins and returns improving?

Cashflow 68

Earnings quality: real cash, not paper profit

Fin. Strength 100

Balance sheet, leverage, solvency risk

Investment 16

Disciplined investing over empire-building

Low Volatility 88

Calm price path (market factor)

Momentum 13

Price trend over the last 3–12 months (market factor)

52W Momentum 14

Distance to the 52-week high (market factor)

Net Issuance 66

Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Full company description

Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X QC Reticles, X QC video tools, and X QC beads; sperm DNA fragmentation test kits; and S10 data consolidation software. Bonraybio Co., Ltd. was founded in 2015 and is based in Taichung, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Bonraybio Co., Ltd. reported revenue of 306M TWD in FY2025 versus 56.3M TWD in FY2021, a compound +52.7%/yr. Reported net income was 103M TWD in FY2025.

Growth Quality 100/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Latest Revenue (FY 2025)

306M TWD

Latest YoY

+37.4%

Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+42.3%

Value creation/yr (3Y, in TWD) ⓘEarnings growth per share (CAGR 3 years) plus dividend yield: value created per share and year. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

≈ +91.4% (approximate, leans on 2025) · in TWD

Earnings growth per share plus dividend yield: the value created per share and year.

Earnings growth per share+89.9%

Dividend yield1.5%

Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−68.4% (2021) → 32.6% (2025) · rising

⚠ Rate leans on 2025: that final year sits 265% above its own trend (e.g. a one-off disposal gain) and could not be adjusted

Revenue +52.7%/yr

FY21 56.3M TWD

FY22 106M TWD

FY23 160M TWD

FY24 223M TWD

FY25 306M TWD

Net income

FY21 −31.7M TWD

FY22 1.7M TWD

FY23 25.7M TWD

FY24 68.4M TWD

FY25 103M TWD

6955 screens 65% overvalued. Compare with Abbott Laboratories, →

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bonraybio Co., Ltd. · Fair Value
60.63 TWD −65%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/6955.TW" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Bonraybio Co., Ltd. · Fair Value</span><br><b style="font-size:20px">60.63 TWD</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−65%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Bonraybio Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6955.TW

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%

Fair Value upside −39% · Below median

Return on equity (TTM) 17% · Top 25%

Return on assets 10% · Top 25%

Net margin (TTM) 33% · Top 25%

Operating margin (TTM) 33% · Top 25%

Revenue growth 16% · Above median

Dividend yield (TTM) 1.5% · Below median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 24.3× · Cheaper than median

P/B 5.16× · Pricier than 75% of peers

P/S (TTM) 9.97× · Pricier than 75% of peers

P/FCF 1.6× · Cheaper than median

EV/EBITDA 26.4× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

This stock

Sector peers

VALUE0 · sector 0

FUTURE79 · sector 32

PAST70 · sector 5

HEALTH0 · sector 97

DIVIDEND30 · sector 35

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$112.47	$74.79	−34%
Stryker Corporation SYK	$322.12	$186.28	−42%
Medtronic plc MDT	$89.97	$65.57	−27%
Boston Scientific Corporation BSX	$46.84	$30.73	−34%
Edwards Lifesciences Corporation EW	$89.78	$41.02	−54%
Siemens Healthineers AG SHL	€39.52	€33.87	−14%
DexCom, Inc DXCM	$90.82	$38.95	−57%
GE HealthCare Technologies Inc GEHC	$74.82	$64.13	−14%
Koninklijke Philips N.V PHIA	€23.69	€14.36	−39%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥150.63	¥147.63	−2%

Compare Bonraybio Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Bonraybio Co., Ltd. (6955) overvalued or undervalued?

As of Aug 28, 2026, our model estimates a fair value of 60.63 TWD versus a price of 100.00 TWD, about −39% upside (overvalued).

What is the fair value of 6955?

Our model-based fair value for Bonraybio Co., Ltd. is 60.63 TWD (as of Aug 28, 2026), built from audited fundamentals. The current price: 100.00 TWD.

What is the quality score of 6955?

Bonraybio Co., Ltd. has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Bonraybio Co., Ltd. (6955)?

Our model-based price target is the fair value of 60.63 TWD (as of Aug 28, 2026) from 26 valuation models. Cautious scenario 47.68 TWD, optimistic scenario 93.52 TWD. It is a calculation from audited fundamentals, not an analyst target.

What is the Bonraybio Co., Ltd. stock forecast for 2026?

Our models put fair value at 60.63 TWD, about −39% upside versus a price of 100.00 TWD (overvalued). Cautious scenario 47.68 TWD, optimistic scenario 93.52 TWD. The calculation is refreshed regularly with new filings.

What is the revenue of Bonraybio Co., Ltd. (6955)?

Bonraybio Co., Ltd. reported trailing-twelve-month revenue of about 320M TWD (latest available figure, as of Aug 28, 2026).

What is the net profit margin of 6955?

The net profit margin of Bonraybio Co., Ltd. is about 32.0%, meaning it keeps roughly 32.0% of revenue as net income. Based on the latest reported figures.

Does Bonraybio Co., Ltd. pay a dividend?

Bonraybio Co., Ltd. currently shows a dividend yield of about 1.50% relative to its recent price (as of Aug 28, 2026).

Free · no account needed

Watch Bonraybio Co., Ltd. in the live analysis

One click puts Bonraybio Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.